Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Reaction Biology Top-Ranked in Kinase Profiling Survey

Published: Wednesday, June 19, 2013
Last Updated: Wednesday, June 19, 2013
Bookmark and Share
RBC also ranked highly on technical support and data quality.

Reaction Biology Corporation ("RBC") has announced that it has received the highest number of positive ratings in a recent industry survey.

HTStec, a UK-based technical research firm, surveyed 78 research labs around the globe for its Kinase Profiling Trends 2013 report. The labs included large pharmas, biotechs, university and non-profit labs.

Survey participants were asked to rate the 16 top kinase profiling outsource providers on eight different attributes.

The provider with the highest number of positive ratings was RBC, which came in number one on customer service, turnaround time, and low cost.

RBC also ranked as the most-used provider to the industry, rising from fifth place in the same survey taken in 2010.

“We are very pleased with this validation of our efforts to provide the widest coverage of the kinome, with a gold standard activity assay,” said Dr. Haiching Ma, Chief Science Officer of RBC.

Dr. Ma continued, “Eighty-eight percent of all pharmas in the survey preferred activity-based assays, and RBC’s radiolabeled HotSpot assay now provides high-quality reproducible data on 457 kinases.”

The survey estimated that RBC had the largest share of the $34 million kinase profiling market.

Based in Malvern, PA, RBC is a premier provider of drug screening and profiling services. With more than 450 kinases, RBC’s coverage of the kinome is the broadest in the industry.

Using its proprietary HotSpotSM technology and other innovations, RBC is expanding its already substantial production of epigenetic regulatory enzymes.

RBC has provided its services to over 300 customers worldwide, including large pharmaceutical, biotech, government, and academic labs.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Reaction Biology and Cisbio Sign Distribution Agreement
Agreement will see Cisbio distribute Reaction Biology's epigenetic proteins.
Friday, January 17, 2014
Scientific News
HIV Patients Should Be Included in Early Clinical Trials of Anti-TB Drugs
Tuberculosis is the number one cause of death in HIV-infected patients in Africa and a leading cause of death in this population worldwide.
Multi-Gene Test Enables Some Breast Cancer Patients to Safely Avoid Chemotherapy
A major study is providing the best evidence to date that a 21-gene test done on the tumor can identify breast cancer patients who can safely avoid chemotherapy.
Low Dose Beta-Blockers As Effective As High Dose After a Heart Attack?
Heart attack patients live as long – or even longer – on one-quarter the suggested dose.
Antidepressants Plus Blood-Thinners Slow Down Brain Cancer
EPFL scientists have found that combining antidepressants with anticoagulants slows down brain tumors (gliomas) in mice.
Old Drug Performs New Tricks
Cambridge-led research reveals the powers of a "wonder drug" that has lain under the noses of doctors for 50 years.
Electronic Reminders Keep TB Patients on Track With Medication In China
Giving electronic reminders to tuberculosis (TB) patients in China can reduce the amount of medication doses they miss by half, according to new research.
Common Drug Presents Fracture Risk To Older Women
Researchers are urging caution in prescribing one of the world’s most commonly issued drug groups, citing links to increased fracture risks in older Australian women.
Combining Epigenetic Therapies and Immunotherapies Improves Cancer Outcomes
Recent data suggest that epigenetic therapies are likely to provide additional clinical benefit to cancer patients when rationally combined with immunotherapeutic drugs.
LiMAx Test Shows Reversibility of Fatty Liver Disease After Obesity Surgery
Clinical study provides evidence for functional liver recovery after weight loss.
Landmark NIH Study Shows Intensive Blood Pressure Management May Save Lives
Lower blood pressure target greatly reduces cardiovascular complications and deaths in older adults.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos